GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

In Vivo Sun Protection Factor Determination

Not Applicable

Completed

Conditions: Skin Care

Interventions: Other: Test Product G
Other: Negative Control
Other: Test Product A
Other: Positive Control
Other: Test Product D
Other: Test Product E
Other: Test Product F
Other: Test Product H
Other: Test Product B
Other: Test Product C

First Posted Date: 2016-06-07

Last Posted Date: 2016-06-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 28

Registration Number: NCT02792595

Locations: 🇩🇪
GSK Investigational Site, Schenefeld, Schleswig-Holstein, Germany

Preference Attributes of ELLIPTA Dry Powder Inhaler (DPI) and HANDIHALER DPI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Phase 4

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo ELLIPTA device
Drug: Placebo capsules for use in HANDIHALER device
Other: Inhaler Preference Questionnaire Version 1
Other: Inhaler Preference Questionnaire Version 2

First Posted Date: 2016-06-01

Last Posted Date: 2018-10-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 214

Registration Number: NCT02786927

Locations: 🇺🇸
GSK Investigational Site, Richmond, Virginia, United States

An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: GSK3326595
Drug: Pembrolizumab

First Posted Date: 2016-05-26

Last Posted Date: 2025-03-10

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 297

Registration Number: NCT02783300

Locations: 🇳🇱
GSK Investigational Site, Rotterdam, Netherlands
🇳🇱
GSK Investigational Site, Rotterdam, Netherlands

Frequency of Denture Cleanser Use and Denture Cleanliness

Not Applicable

Completed

Conditions: Denture Cleansers

Interventions: Device: Denture Cleanser Daily Use Period
Device: Denture Cleanser Weekly Use Period
Other: Water

First Posted Date: 2016-05-23

Last Posted Date: 2018-12-24

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 19

Registration Number: NCT02780661

Locations: 🇬🇧
GSK Investigational Site, Glasgow, United Kingdom

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Repeat Doses of GSK2982772 in Subjects With Psoriasis

Phase 2

Completed

Conditions: Psoriasis

Interventions: Drug: GSK2982772
Drug: Placebo

First Posted Date: 2016-05-18

Last Posted Date: 2020-07-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 65

Registration Number: NCT02776033

Locations: 🇨🇦
GSK Investigational Site, Montreal, Quebec, Canada

Study to Investigate the Efficacy of an Occluding Dentifrice in Providing Relief From Dentine Hypersensitivity

Phase 4

Completed

Conditions: Dentin Sensitivity

Interventions: Other: Sodium monofluorophosphate Dentifrice
Other: Stannous Fluoride Dentifrice

First Posted Date: 2016-05-16

Last Posted Date: 2017-09-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 143

Registration Number: NCT02773758

Locations: 🇨🇦
GSK Investigational Site, Mississauga, Ontario, Canada

Dentine Tubule Occlusion Assessment in a Modified in Situ Model

Not Applicable

Completed

Conditions: Dentin Sensitivity

Interventions: Device: Stannous fluoride
Other: Sodium monofluorophosphate
Other: Mineral water

First Posted Date: 2016-05-11

Last Posted Date: 2018-06-25

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT02768194

Locations: 🇬🇧
GSK Investigational Site, Bristol, United Kingdom

This Study Will Describe the Burden of DENgue Fever Virus (DENV) Illness Among Household Members Aged 6 Months to 50 Years of Selected Communities in Latin America and Southeast Asia

Not Applicable

Terminated

Conditions: Dengue Vaccines
Dengue

Interventions: Procedure: Blood sample collection

First Posted Date: 2016-05-09

Last Posted Date: 2024-03-15

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1750

Registration Number: NCT02766088

Locations: 🇵🇭
GSK Investigational Site, Muntinlupa, Philippines

A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.

Completed

Conditions: Diphtheria

Interventions: Biological: Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]

First Posted Date: 2016-05-02

Last Posted Date: 2019-10-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 2462

Registration Number: NCT02757950

Locations: 🇧🇷
GSK Investigational Site, Santo Andre, São Paulo, Brazil

Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years

Phase 4

Completed

Conditions: Prostatic Hyperplasia

Interventions: Other: Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool
Other: International Prostate Symptom Score (IPSS) screening tool

First Posted Date: 2016-05-02

Last Posted Date: 2021-01-05

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1679

Registration Number: NCT02757963

Locations: 🇪🇸
GSK Investigational Site, Valencia, Spain

Home Terms & Conditions Privacy Policy